Mistletoe plant extract in patients with nonmuscle invasive bladder cancer: Results of a phase Ib/IIa single group dose escalation study

Journal of Urology

Volumn 194, Issue 4, 2015, Pages 939-943

  Rose, Achim ^a   El Leithy, Tarek ^d   Dorp, Frank Vom ^a   Zakaria, Ahmed ^d   Eisenhardt, Andreas ^b   Tschirdewahn, Stephan ^c   Rübben, Herbert ^c  

^a Department of Urology HELIOS Marien Klinik   (Germany)

^b PUR/R Praxisklinik Urologie Rhein Ruhr   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

Author keywords

abnoba viscum; administration; intravesical; mistletoe; treatment outcome; urinary bladder neoplasms

Indexed keywords

HEMOGLOBIN VARIANT; VISCUM ALBUM EXTRACT; PLANT EXTRACT;

ADULT; ARTICLE; BLADDER BIOPSY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYSTOSCOPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEUKOCYTURIA; MALE; MAXIMUM TOLERATED DOSE; NON MUSCLE INVASIVE BLADDER CANCER; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECURRENCE RISK; SIDE EFFECT; TRANSURETHRAL RESECTION; TUMOR BIOPSY; TUMOR REGRESSION; URINARY TRACT INFECTION; CLINICAL TRIAL; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; MISTLETOE; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHYTOTHERAPY; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MISTLETOE; NEOPLASM INVASIVENESS; PHYTOTHERAPY; PLANT EXTRACTS; URINARY BLADDER NEOPLASMS;

EID: 84941599304     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.04.073     Document Type: Article

References (30)

1. M. Babjuk, M. Burger, R. Zigeuner, and et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder, Update 2013 Eur Urol 64 2013 639
2. R. Sylvester, W. Oosterlinck, and A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186
3. R. Sylvester, A. van der Meijden, J.A. Witjes, and et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 2005 90
4. H. Huland, O. Otto, M. Drose, and et al. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival J Urol 132 1984 27
5. L.R. Kavoussi, J.R. Torrence, D.P. Gillen, and et al. Results of six weekly intravesical BCG instillations on the treatment of superficial bladder carcinoma J Urol 139 1988 935
6. M.F. Sarosdy, and D.L. Lamm Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer J Urol 142 1989 719
7. T. Okamura, K. Tozawa, Y. Yamada, and et al. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer J Urol 156 1996 967
8. S. Krege, G. Giani, T. Meyer, and et al. A randomized trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus Calmette-Guerin J Urol 156 1996 962
9. R.L. Deresiewicz, R.M. Stone, and J.C. Aster Fatal disseminated mycobacterial infection following intravesical BCG J Urol 144 1990 1331
10. D.L. Lamm, V.D. Stogdill, B.J. Stogdill, and et al. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer J Urol 135 1986 272
11. D.L. Lamm, P.M. van der Meijden, A. Morales, and et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer J Urol 147 1992 596
12. W.H. Rawls, D.L. Lamm, B.A. Lowe, and et al. Fatal sepsis following intravesical BCG administration for bladder cancer J Urol 144 1990 1328
13. P.J. Goebell, T. Otto, J. Suhr, and et al. Evaluation of unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial J Urol 168 2002 72
14. A.M. Burger, U. Mengs, J.B. Schüler, and et al. Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro Arzneimittelforschung 51 2001 748
15. K. Urech, A. Buessing, G. Thalmann, and et al. Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines Anticancer Res 26 2006 3049
16. U. Elsasser-Beile, T. Ruhnau, N. Freudenberg, and et al. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model Cancer 91 2001 998
17. U. Mengs, T. Schwarz, M. Bulitta, and et al. Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice Anticancer Res 20 2000 3565
18. H.J. Luboldt, T. Otto, J. Suhr, and et al. Komplementärmedizin des Harnblasenkarzinoms Urol(B) 42 2002 293
19. B.E. Storer Design and analysis of phase I clinical trials Biometrics 45 1989 925
20. O.N. Gofrit, K.C. Zorn, S. Shikanov, and et al. Marker lesion experiments in bladder cancer - what have we learned? J Urol 183 2010 1678
21. A.P. Van der Meijden, R.R. Hall, M.P. Macaluso, and et al. Marker tumor response to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumors Eur Urol 29 1996 199
22. A.P. Van der Meijden, R.R. Hall, K.H. Kurth, and et al. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept Br J Urol 77 1996 634
23. A.P. Van der Meijden The use of the marker tumor concept in Ta, T1 bladder cancer: Is it justified? Urol Oncol 7 2002 31
24. N.M. Heney, W.W. Koontz, B. Barton, and et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1, and Tis transitional cell carcinoma of the bladder: a phase III prospective randomized study J Urol 140 1988 1390
25. T. Mishina, K. Oda, S. Murata, and et al. Mitomycin C bladder instillation therapy for bladder tumors J Urol 114 1975 217
26. A.V. Bono, R.R. Hall, L. Denis, and et al. Chemoresection in Ta-T1 bladder cancer Eur Urol 29 1996 385
27. P.U. Malmström A randomized comparative dose-ranging study of interferon-α and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder BJU Int 89 2002 681
28. R. Colombo, M. Brausi, L. Da Pozzo, and et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication - a pilot study on marker lesion Eur Urol 39 2001 95
29. M.C. Hall, S.S. Chang, G. Dalbagni, and et al. Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1 and Tis: Update 2007) 2007 American Urological Association Linthicum
30. M. Babjuk, M. Burger, R. Zigeuner, and et al. Guidelines on Non-Muscle Invasive Bladder Cancer (TaT1 and CIS) 2013 European Association of Urology Arnhem, The Netherlands